Nexalin targets Q2 2026 enrollment for pivotal HALO Clarity insomnia trial

• Nexalin Technology advanced plans for pivotal clinical trial of HALO Clarity device for moderate-to-severe insomnia, with patient enrollment expected to start in Q2 2026.
• Study will be randomized, triple-blinded, sham-controlled, enrolling 160 participants.
• Trial is intended to support planned FDA De Novo Classification Request, aiming to establish HALO Clarity as a new device category.
• No new study results were presented; prior peer-reviewed data has been cited as showing improvements versus sham treatment.
• Program positioning targets drug-free insomnia treatment, with management framing it as a potential differentiated option if trial and regulatory milestones are met.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220935PRIMZONEFULLFEED9694870) on April 22, 2026, and is solely responsible for the information contained therein.